Celsior® is an organ preservation solution used for the harvesting and the preservation of solid organs. Its use as a crystalloid cardioplegia solution has been established recently. Its main advantage is the long duration of myocardial protection. Compared to the other cardioplegia solutions, it allows a reduced amount of solution administered during the surgery and fewer interruptions during the intervention for the administration of supplemental doses of cardioplegia for long and complex operations. The objective of this register is to compare the safety and the efficacy of Celsior® to the old cardioplegia solution Saint-Thomas used as cardioplegia solution in surgery of the transposition of great vessels, the arterial switch operation.
Study Type
OBSERVATIONAL
Enrollment
200
Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
: Hôpital Louis Pradel - Service de Chirurgie Cardiaque C
Bron, France
RECRUITINGDeath at 30 days after surgery
Death at 30 days after surgery
Time frame: 30 days
Post-operative troponin levels
Troponin in ng/L
Time frame: 48 hours
Cardiac rhythm assessment
Percentage of abnormal rhythm
Time frame: 24 hours
Variation of pre- and post-operative creatinine levels
Creatinine in µmol/L
Time frame: 24 hours
Intensive care unit length of stay
In days
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.